227 related articles for article (PubMed ID: 32291236)
1. SPAG5: An Emerging Oncogene.
He J; Green AR; Li Y; Chan SYT; Liu DX
Trends Cancer; 2020 Jul; 6(7):543-547. PubMed ID: 32291236
[TBL] [Abstract][Full Text] [Related]
2. SPAG5 promotes hepatocellular carcinoma progression by downregulating SCARA5 through modifying β-catenin degradation.
Liu H; Hu J; Wei R; Zhou L; Pan H; Zhu H; Huang M; Luo J; Xu W
J Exp Clin Cancer Res; 2018 Sep; 37(1):229. PubMed ID: 30249289
[TBL] [Abstract][Full Text] [Related]
3. A genome-wide enrichment screen identifies NUMA1-loss as a resistance mechanism against mitotic cell-death induced by BMI1 inhibition.
Gisler S; Maia ARR; Chandrasekaran G; Kopparam J; van Lohuizen M
PLoS One; 2020; 15(4):e0227592. PubMed ID: 32343689
[TBL] [Abstract][Full Text] [Related]
4. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
5. SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway.
Yuan LJ; Li JD; Zhang L; Wang JH; Wan T; Zhou Y; Tu H; Yun JP; Luo RZ; Jia WH; Zheng M
Cell Death Dis; 2014 May; 5(5):e1247. PubMed ID: 24853425
[TBL] [Abstract][Full Text] [Related]
6. SPAG5 interacts with CEP55 and exerts oncogenic activities via PI3K/AKT pathway in hepatocellular carcinoma.
Yang YF; Zhang MF; Tian QH; Fu J; Yang X; Zhang CZ; Yang H
Mol Cancer; 2018 Aug; 17(1):117. PubMed ID: 30089483
[TBL] [Abstract][Full Text] [Related]
7. High expression of SPAG5 sustains the malignant growth and invasion of breast cancer cells through the activation of Wnt/β-catenin signalling.
Jiang J; Wang J; He X; Ma W; Sun L; Zhou Q; Li M; Yu S
Clin Exp Pharmacol Physiol; 2019 Jun; 46(6):597-606. PubMed ID: 30854682
[TBL] [Abstract][Full Text] [Related]
8. Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex.
Gkountakos A; Pilotto S; Mafficini A; Vicentini C; Simbolo M; Milella M; Tortora G; Scarpa A; Bria E; Corbo V
Carcinogenesis; 2018 Jul; 39(8):971-980. PubMed ID: 29955840
[TBL] [Abstract][Full Text] [Related]
9. SPAG5 contributes to the progression of gastric cancer by upregulation of Survivin depend on activating the wnt/β-catenin pathway.
Liu G; Liu S; Cao G; Luo W; Li P; Wang S; Chen Y
Exp Cell Res; 2019 Jun; 379(1):83-91. PubMed ID: 30904482
[TBL] [Abstract][Full Text] [Related]
10. p53 suppression is essential for oncogenic SPAG5 upregulation in lung adenocarcinoma.
Wang T; Li K; Song H; Xu D; Liao Y; Jing B; Guo W; Hu M; Kuang Y; Sun B; Ling J; Zhang T; Xu J; Yao F; Deng J
Biochem Biophys Res Commun; 2019 May; 513(2):319-325. PubMed ID: 30955859
[TBL] [Abstract][Full Text] [Related]
11. Targeting CTGF in Cancer: An Emerging Therapeutic Opportunity.
Shen YW; Zhou YD; Chen HZ; Luan X; Zhang WD
Trends Cancer; 2021 Jun; 7(6):511-524. PubMed ID: 33358571
[TBL] [Abstract][Full Text] [Related]
12. miR-539 inhibits prostate cancer progression by directly targeting SPAG5.
Zhang H; Li S; Yang X; Qiao B; Zhang Z; Xu Y
J Exp Clin Cancer Res; 2016 Apr; 35():60. PubMed ID: 27037000
[TBL] [Abstract][Full Text] [Related]
13. Sperm-Associated Antigen 5 Expression Is Increased in Hepatocellular Carcinoma and Indicates Poor Prognosis.
Zhou H; Wang SC; Ma JM; Yu LQ; Jing JS
Med Sci Monit; 2018 Aug; 24():6021-6028. PubMed ID: 30157168
[TBL] [Abstract][Full Text] [Related]
14. Cdc6 as a novel target in cancer: Oncogenic potential, senescence and subcellular localisation.
Lim N; Townsend PA
Int J Cancer; 2020 Sep; 147(6):1528-1534. PubMed ID: 32010971
[TBL] [Abstract][Full Text] [Related]
15. SPAG5 promotes proliferation and suppresses apoptosis in bladder urothelial carcinoma by upregulating Wnt3 via activating the AKT/mTOR pathway and predicts poorer survival.
Liu JY; Zeng QH; Cao PG; Xie D; Yang F; He LY; Dai YB; Li JJ; Liu XM; Zeng HL; Fan XJ; Liu L; Zhu YX; Gong L; Cheng Y; Zhou JD; Hu J; Bo H; Xu ZZ; Cao K
Oncogene; 2018 Jul; 37(29):3937-3952. PubMed ID: 29662193
[TBL] [Abstract][Full Text] [Related]
16. EGFR-mediated autophagy in tumourigenesis and therapeutic resistance.
Wu M; Zhang P
Cancer Lett; 2020 Jan; 469():207-216. PubMed ID: 31639425
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of super enhancer-derived noncoding RNAs in human cancer.
Wang Y; Nie H; He X; Liao Z; Zhou Y; Zhou J; Ou C
Theranostics; 2020; 10(24):11049-11062. PubMed ID: 33042269
[TBL] [Abstract][Full Text] [Related]
18. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure.
Pagliarini R; Shao W; Sellers WR
EMBO Rep; 2015 Mar; 16(3):280-96. PubMed ID: 25680965
[TBL] [Abstract][Full Text] [Related]
19. Anti-mitotic therapies in cancer.
Tischer J; Gergely F
J Cell Biol; 2019 Jan; 218(1):10-11. PubMed ID: 30545842
[TBL] [Abstract][Full Text] [Related]
20. PAQR4 oncogene: a novel target for cancer therapy.
Patil D; Raut S; Joshi M; Bhatt P; Bhatt LK
Med Oncol; 2024 May; 41(6):161. PubMed ID: 38767705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
